SCHEMBL29967917

SCHEMBL29967917

Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)N(Cc3cnc5[nH]nc(C)c5c3)CC4)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DDR1 Q08345 8/20 0.56
▸ DDR2 Q16832 5/20 0.56
▸ NTRK3 Q16288 4/20 0.56
▸ NTRK1 P04629 3/20 0.56
▸ NTRK2 Q16620 3/20 0.56
▸ NR2E1 Q9Y466 3/20 0.52
▸ ABL1 P00519 8/20 0.51
▸ KIT P10721 2/20 0.51
▸ PDGFRB P09619 1/20 0.51
▸ BCR P11274 6/20 0.49
▸ EPHB2 P29323 1/20 0.49
▸ MAPK14 Q16539 1/20 0.48
▸ MAP3K20 Q9NYL2 1/20 0.48
▸ MUSK O15146 1/20 0.48
▸ CDK11B P21127 1/20 0.48
▸ EPHA8 P29322 1/20 0.48
▸ CDK11A Q9UQ88 1/20 0.48
▸ LDLR P01130 1/20 0.48
▸ PCSK9 Q8NBP7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081377 1.00 DDR1 (0.56) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27081680 0.89 ABL1 (0.61) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27081565 0.87 MAPK14 (0.54) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL29939696 0.87 DDR1 (0.65) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27082304 0.87 DDR1 (0.65) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL29968231 0.86 WNT1 (0.42) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27081627 0.86 WNT1 (0.42) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL29967389 0.85 DDR2 (0.51) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL29968090 0.85 DDR2 (0.56) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27081794 0.85 DDR2 (0.51) DDR1DDR2NTRK3NTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 DDR1 1/4885DDR2 2/4885NTRK3 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback